Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
27.14
+0.36 (+1.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma Plc Cl A
< Previous
1
2
Next >
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 24, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
August 24, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Royalty Pharma Reports Second Quarter 2023 Results
August 08, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2023 Dividend
July 17, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
March 23, 2023
From
PureTech Health plc
Via
Business Wire
Royalty Pharma Raises Full Year 2023 Guidance
March 15, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
March 01, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 18, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
January 04, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Expansion of Senior Leadership Team
December 15, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 28, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 09, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Royalty Pharma Reports Third Quarter 2022 Results
November 08, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
